The ClearSeq AML HS, designed in collaboration with Dr. Robert Ohgami and Dr. Daniel Arber at Stanford University, is a targeted NGS panel for acute myeloid leukemia (AML). This panel targets selected exons in 20 genes that are commonly mutated in AML.
Compatible with the HaloPlexHS technology, the ClearSeq AML HS provides molecular barcodes-enabled error correction for confident detection of somatic variants at below 1% allele frequency. With an accelerated workflow, sequencing-ready libraries are generated from 50 ng DNA in under 6 hours.
For Research Use Only. Not for use in diagnostic procedures.